Published in Sci Rep on July 27, 2012
Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol (2014) 1.71
Functions of lncRNA HOTAIR in lung cancer. J Hematol Oncol (2014) 1.23
Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia (2013) 1.03
The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer (2013) 1.02
Systems biology approach to stage-wise characterization of epigenetic genes in lung adenocarcinoma. BMC Syst Biol (2013) 0.87
Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. Int J Oncol (2013) 0.86
Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells. Stem Cells (2015) 0.85
Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Mol Carcinog (2014) 0.81
lincRNA HOTAIR as a novel promoter of cancer progression. J Can Res Updates (2014) 0.80
Signaling to NF-kappaB. Genes Dev (2004) 19.78
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet (2008) 17.67
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 11.29
The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol (2002) 10.59
The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell (1995) 8.80
Epithelial-mesenchymal transitions: twist in development and metastasis. Cell (2004) 7.14
Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem (2000) 6.74
TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science (1995) 6.41
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med (1999) 4.40
NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene (2006) 3.91
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol (1997) 3.76
Two tumour necrosis factor receptors: structure and function. Trends Cell Biol (1995) 3.67
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem (1995) 2.78
Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res (2006) 2.73
The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res (2003) 2.67
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest (2009) 2.42
Modulation of life and death by the TNF receptor superfamily. Oncogene (1998) 2.18
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A (2000) 1.94
Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem (1996) 1.85
Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell (2005) 1.82
Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J (1999) 1.59
NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia (2003) 1.47
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene (2011) 1.34
Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer (1999) 1.33
Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res (1998) 1.32
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res (2006) 1.31
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat (2009) 1.29
Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis. Dev Dyn (2008) 1.29
Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther (2004) 1.28
Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther (2011) 1.24
Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology (2008) 1.15
Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res (1997) 1.12
Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet (2007) 1.10
Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol (2011) 1.09
Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem (1994) 1.07
TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene (2006) 1.04
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol (2004) 1.04
NF-kappaB and breast cancer. Curr Probl Cancer (2002) 0.98
Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem (2009) 0.98
Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. J Biol Chem (1997) 0.98
Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. Cancer Res (1994) 0.95
Breaking the 'harmony' of TNF-α signaling for cancer treatment. Oncogene (2011) 0.92
NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells. J Cell Biochem (2009) 0.92
Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev (2001) 0.91
Sphingolipids as determinants of apoptosis and chemoresistance in the MCF-7 cell model system. Exp Biol Med (Maywood) (2009) 0.90
Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer (1999) 0.90
Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res (2003) 0.89
Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol (2000) 0.89
Impact of multicellular resistance on the survival of solid tumors, including micrometastases. Invasion Metastasis (1995) 0.89
Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol (2010) 0.89
Prognostic relevance of transforming growth factor alpha (TGF-alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry. Breast Cancer Res Treat (1994) 0.83
Dual inhibition of sphingosine kinase isoforms ablates TNF-induced drug resistance. Oncol Rep (2012) 0.83
Toll-like receptor 9 agonist inhibits ERalpha-mediated transactivation by activating NF-kappaB in breast cancer cell lines. Oncol Rep (2009) 0.82
TNF alpha-induced down-regulation of estrogen receptor alpha in MCF-7 breast cancer cells. Mol Cells (2008) 0.82
The development of human tumor-cell resistance to TNF-alpha does not confer resistance to cytokine-induced cellular cytotoxic mechanisms. Int J Cancer (1992) 0.81
Sphingosine kinase: a promising cancer therapeutic target. Cancer Biol Ther (2011) 0.80
Tumor necrosis factor receptor 1 functions as a tumor suppressor. Am J Physiol Gastrointest Liver Physiol (2011) 0.80
Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. J Endocrinol (2012) 0.79
Chemotherapy for advanced breast cancer: a current perspective. Semin Oncol (1996) 0.77
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol (2004) 2.41
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther (2009) 2.21
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Res (2009) 2.03
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Alcohol alters DNA methylation patterns and inhibits neural stem cell differentiation. Alcohol Clin Exp Res (2011) 1.88
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood (2010) 1.84
Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol (2009) 1.82
CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol Endocrinol (2005) 1.66
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol (2005) 1.53
Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation. Epigenetics (2009) 1.53
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res (2012) 1.51
Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray. Nucleic Acids Res (2004) 1.50
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics (2008) 1.49
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog (2013) 1.43
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41
Absence of functional EpoR expression in human tumor cell lines. Blood (2010) 1.41
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther (2005) 1.40
MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta (2011) 1.39
Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res (2003) 1.38
Patients with spina bifida and bladder cancer: atypical presentation, advanced stage and poor survival. J Urol (2007) 1.38
Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem (2006) 1.35
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer (2010) 1.34
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res (2006) 1.31
The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol (2002) 1.30
Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction. J Clin Invest (2013) 1.29
Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology (2010) 1.29
Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat (2009) 1.29
Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther (2004) 1.28
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther (2010) 1.28
Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics (2008) 1.27
Identification of mitogen-activated protein kinase kinase as a chemoresistant pathway in MCF-7 cells by using gene expression microarray. Surgery (2002) 1.27
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol (2009) 1.26
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet (2013) 1.24
Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther (2011) 1.24
Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res (2006) 1.21
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res (2005) 1.20
Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. Genome Res (2010) 1.18
Human cytomegalovirus infection dysregulates the canonical Wnt/β-catenin signaling pathway. PLoS Pathog (2012) 1.18
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest (2010) 1.17
Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology (2008) 1.15
Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res (2011) 1.15
Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen. J Hematol Oncol (2013) 1.15
Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res (2012) 1.14
Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol (2008) 1.14
GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Lett (2011) 1.09
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell (2013) 1.09
Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol (2004) 1.09
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol Cancer (2010) 1.08
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia (2008) 1.08